Taxotere® (docetaxel) receives 2 new European approvals for treatment of breast cancer

12-Jan-2005

Sanofi-aventis announced that the European Commission has approved 2 new indications for Taxotere® (docetaxel) Injection Concentrate for treatment of breast cancer.

The first granted Taxotere®, in combination with doxorubicin and cyclophosphamide, for the adjuvant treatment of patients with operable node-positive breast cancer.

A second granted Taxotere®, in combination with Herceptin® (trastuzumab), for the treatment of patients with metastatic breast cancer whose tumors over-express the Her2 gene.

The Commission approval is based on the results of two separate large randomized international trials.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances